Connect Biopharma logo
Connect Biopharma
CNTB | NASDAQ
Chart Builder DCF Calculator
$0.64
-$0.04 (-5.49%)
At close: Nov 16, 2026, 4:00 PM ET
$0.59
-$0.05 (-8.23%)
After-hours: Nov 16, 2026, 7:57 PM ET

Connect Biopharma Company Profile

Company profile explained

Company Profile

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.

Key Executives

Name Position
Barry D. Quart Chief Executive Officer & Director
David L. Szekeres President
Jeff Cohn General Counsel & Corporate Secretary
Kimberly J. Manhard Executive Vice President & Chief Development Officer
Lei Sun Vice President of Biologics & Head of CMC
Lisa Peraza Senior Vice President of Finance
Sean T. Ristine Vice President of Human Resources
Srikanth Pendyala Senior Vice President of Clinical Development(Consultant)

Latest SEC Filings

Date Type Title
Oct 06, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 01, 2026 4 Filing
Oct 01, 2026 4 Filing
Sep 30, 2026 8-K Current Report
Sep 15, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 12, 2026 10-Q Quarterly Report
Aug 12, 2026 8-K Current Report
Jul 01, 2026 4 Filing
View All SEC Filings ➞
Connect Biopharma
Connect Biopharma logo
Country United States
IPO Date Mar 19, 2021
Industry Biotechnology
Sector Healthcare
Employees 64
CEO Barry D. Quart

Contact Details

3580 Carmel Mountain Road San Diego, California 92130 United States

Stock Details

Ticker Symbol CNTB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001835268
CUSIP Number G23549101
ISIN Number KYG235491019
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.